Researchers report a significant advance in the search for medications that can suppress pain but avoid opioids’ abuse potential and other undesirable CNS effects. A new compound reduces mouse responses in animal models of neurogenic and chronic inflammatory (e.g., arthritic) pain. The compound, called UB937, enhances the natural pain-killing activity of the neurotransmitter anandamide, and exerts its analgesic effects entirely in peripheral tissues, without entering the brain.
A new vaccine hindered the often-abused prescription opioids oxycodone and hydrocodone from entering the brain and suppressed one of the drugs’ signature central nervous system effects. The findings warrant continued development of the vaccine as a potential aid in the treatment of oxycodone and hydrocodone abuse and dependence.
More than half of heroin-addicted patients treated with naltrexone via an implanted delivery device maintained abstinence throughout a 6-month clinical trial in Saint Petersburg, Russia. The implant device, which releases a steady dose of naltrexone continuously for 2 months, averted relapse to heroin use three times as effectively as daily oral doses of the medication.
Clinical trials of N-acetylcysteine to help people recovering from drug abuse avoid relapse have demonstrated only moderate efficacy. New NIDA-supported research shows that while a low dose of the medication activates receptors associated with lowered drug-seeking behavior, a higher dose appears to activate receptors associated with increased drug-seeking behavior. The result suggests that a medication or combination of medications that stimulate the receptor GluR2/3 and block mGluR5 may work better than N-acetylcysteine alone.
Describes findings from two randomized clinical trials showing that treatment with multidimensional family therapy resulted in fewer drug-related problems than treatment with cognitive behavior therapy.